Business Context and Reporting Period
This Form 8-K was filed by Oncobiologics, Inc. (noting the metadata reference to Outlook Therapeutics, Inc.) on June 28, 2017. The company is incorporated in Delaware and operates as an emerging growth company. The report addresses a specific regulatory event regarding its listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the market value of listed securities, which fell below the required threshold of $50,000,000 as of June 28, 2017. The filing also notes the company failed to meet alternative listing standards based on minimum stockholders' equity or total assets/total revenue, though specific figures for these items are not provided.
Material Changes
The material change reported is the receipt of written notification from Nasdaq indicating non-compliance with continued listing rules. Specifically, the company failed to meet the $50,000,000 minimum market value of listed securities requirement under Nasdaq Marketplace Rule 5450(b)(2)(A). This notification has no immediate effect on the listing of the company's common stock.
Outlook, Risks, and Contingencies
- Compliance Period: The company has 180 calendar days from the notification date to regain compliance.
- Compliance Requirement: To remain listed, the market value of listed securities must close at $50,000,000 or more for a minimum of 10 consecutive business days.
- Delisting Risk: If compliance is not achieved within the 180-day period, the company may receive a delisting determination. At that time, the company may request a hearing to remain on the Nasdaq Global Market, which would suspend the delisting determination pending a decision.
- Uncertainty: Management explicitly states there can be no assurance that the company will be successful in regaining compliance or maintaining its listing.
Investor Verification Checklist
- Verify the current market capitalization and whether it has sustained the $50,000,000 threshold for 10 consecutive business days.
- Monitor the company's stock price volatility and trading volume over the 180-day compliance window.
- Check for any subsequent filings regarding a hearing request or a formal delisting determination from Nasdaq.
- Review the company's balance sheet to understand the specific stockholders' equity and asset/revenue figures that failed the alternative listing standards.